Januvia(Sitagliptin Phosphate)
MRK
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Merck & Co., Inc.
$3.81B
Medicare cost, 2024
$3.81B
Medicare cost, 2024
Medicare drug plans spent $3.8 billion on Januvia (sitagliptin phosphate) in 2024, for 4.0 million prescriptions and refills filled by 827,991 patients. It ranks 12th among all drugs by Medicare drug plan spending. California accounts for the most spending ($434.3 million, 11% of the total). It is made by Merck & Co., Inc. (MRK).
Medicare cost, 2024
$3.81B
-6.9% from 2023
Prescriptions
4.0M
$945.51 per claim
Patients
828K
231,789 prescribers
Total spending, 2024
$3.81B
$4,597.26 per patient
Questions and answers
How much does Medicare spend on Januvia?
Medicare prescription drug plans paid $3.81B for Januvia in 2024, for 4,025,920 prescriptions and refills to 827,991 patients (down 6.9% from 2023). The average cost per claim was $945.51.
Which state spends the most on Januvia?
California had the highest Medicare cost for Januvia in 2024: $434.3M for 461,907 claims, followed by New York ($389.8M).
Who prescribes Januvia the most?
Bin Wang, internal medicine in Flushing, NY, had the highest Medicare cost for Januvia in 2024: 1,165 claims costing $886K.
Who makes Januvia?
Januvia is made by Merck & Co., Inc. (MRK), listed in the Medicare spending data as Merck Sharp & D.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Januvia was $3.81B in 2024, after a high of $4.10B in 2022.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Januvia, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Bin Wang Flushing, NY | Internal Medicine | 1,165 | 164 | $886K |
| Kelvin Mai Santa Ana, CA | Internal Medicine | 946 | 160 | $739K |
| Rodolfo Guzman Bronx, NY | Endocrinology | 649 | 150 | $706K |
| Hossam H Amin Brooklyn, NY | Pulmonary Disease | 940 | 131 | $676K |
| Xiangsheng Zheng Birmingham, AL | Internal Medicine | 1,101 | 138 | $634K |
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 877 | 165 | $626K |
| Jose L Vega III Yuma, AZ | Family Practice | 461 | 142 | $550K |
| Sonwoo Lee Los Angeles, CA | Internal Medicine | 818 | 98 | $531K |
| Saleh Khaddash Clifton, NJ | Endocrinology | 537 | 135 | $521K |
| Jose R Baez Lawrence, MA | Internal Medicine | 825 | 150 | $509K |
| Pankaj Shukla Bakersfield, CA | Internal Medicine | 618 | 115 | $504K |
| Mauricio E Jimenez El Paso, TX | Internal Medicine | 350 | 111 | $495K |
| Ajay G Meka Santa Ana, CA | Internal Medicine | 441 | 130 | $474K |
| Eugenio Angueira-Serrano Miami, FL | Endocrinology | 675 | 151 | $468K |
| Paul H Deutsch Norwich, CT | Internal Medicine | 366 | 89 | $468K |
| Benito A Marranzini El Paso, TX | Endocrinology | 359 | 124 | $467K |
| Jason S Paek Rowland Heights, CA | Internal Medicine | 646 | 103 | $463K |
| Pankaj V Patel Edison, NJ | Internal Medicine | 450 | 98 | $457K |
| Stanley Kim Edison, NJ | Nephrology | 566 | 85 | $453K |
| Jaime F Lopez-Santini New York, NY | Internal Medicine | 372 | 94 | $448K |
| Paramjit S Takhar Sacramento, CA | Family Practice | 411 | 108 | $446K |
| Sixto R Caro Brooklyn, NY | Internal Medicine | 511 | 94 | $441K |
| Muhammad Bakleh Flint, MI | Endocrinology | 440 | 112 | $433K |
| Mohammad A Chaudhry Union City, NJ | Internal Medicine | 419 | 87 | $432K |
| Yong S Lin New York, NY | Internal Medicine | 526 | 77 | $429K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 231,037 | 4,241,351 | 884,560 | $4.10B |
| 2023 | 230,818 | 4,027,265 | 842,948 | $4.09B |
| 2024 | 231,789 | 4,025,920 | 827,991 | $3.81B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Merck Sharp & D | 4,027,317 | $3.81B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 24
- RxNorm concept IDs
- 2709603, 2709608, 2709612, 665036, 665040
- Application numbers
- NDA021995
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 72,500 side-effect reports named sitagliptin, the active ingredient of Januvia (reports from 2006 on). 46,832 of them (64.6%) were serious, 6,841 named a death and 25,279 named a hospital stay. The reactions named most often were blood glucose increased, nausea and diarrhoea. 14,206 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
72,500
2,807 in 2025 (-1.6% from 2024)
Serious
64.6%
46,832 reports
Deaths named
6,841
9.4% of reports
Hospital stays
25,279
34.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Januvia?
72,500 reports from 2006 through September 2026 named sitagliptin, the active ingredient of Januvia. 46,832 of them (64.6%) were serious, 6,841 named a death and 25,279 named a hospital stay.
What are the most reported side effects of Januvia?
4,522 reports named blood glucose increased, the reaction named most often, followed by nausea (3,969) and diarrhoea (3,635). In the last 5 years the reaction named most often was product dose omission issue (1,066 reports). A report can name several reactions.
How many side-effect reports named Januvia in 2025?
2,807 reports were received in 2025 (-1.6% from 2024). 2026 so far: 2,035 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Januvia caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Januvia caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with sitagliptin: Sitagliptin
- Makers on the stock market:
MRK·MRK drug pipeline - Drug approvals (4 approvals on file for sitagliptin) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (sitagliptin) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.